Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology CFO Jason O'Byrne to step down effective August 3, 2026

Neutral Impact 4 of 5 leadership Written later

Vir Biotechnology's Chief Financial Officer, Jason O'Byrne, will step down effective August 3, 2026 to pursue another opportunity, and the company says his departure was not due to any disagreement on its operations, policies, or practices. The board has named Brent Sabatini, the company's Chief Accounting Officer, as interim principal financial officer effective the same date while Vir searches for a successor, a change that matters to shareholders because it concerns who leads financial reporting during the transition.

Key points

  • Jason O'Byrne, Executive Vice President and Chief Financial Officer, informed Vir on July 20, 2026 that he will step down effective August 3, 2026.
  • The board appointed Brent Sabatini, Senior Vice President and Chief Accounting Officer, as interim principal financial officer on July 23, 2026, effective August 3, 2026.
  • Sabatini has served as Chief Accounting Officer since February 2023 and as principal accounting officer since October 2024; he will receive no added compensation for the interim role.
  • Vir has initiated a search for O'Byrne's successor; the filing gives no timeline for that search.

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECJul 24, 2026, 8:31 AM ET
Accession number0001628280-26-049499

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.